Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 4 25 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 4 25 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
Travasol 2.75% in Dextrose 15% is a parenteral nutrition solution. Travassol provides amino acids for protein synthesis, while dextrose provides caloric energy. The mechanism involves intravenous administration to bypass gastrointestinal absorption, directly delivering substrates for metabolism and tissue repair.
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.
None Documented
None Documented
Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia).
The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution